[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Stebbins JL, De SK, Machleidt T, Becattini B, Vazquez J, Kuntzen C, Chen LH, Cellitti JF, Riel-Mehan M, Emdadi A, Solinas G, Karin M, Pellecchia M: Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A; 2008 Oct 28;105(43):16809-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a new JNK inhibitor targeting the JNK-JIP interaction site.
  • In animal studies, BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes.
  • In view of its favorable inhibition profile, selectivity, and ability to function in the cellular milieu and in vivo, BI-78D3 represents not only a JNK inhibitor, but also a promising stepping stone toward the development of an innovative class of therapeutics.

  • BindingDB. BindingDB .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 1;18(45):6158-62 [10557107.001]
  • [Cites] Diabetes. 2001 Jan;50(1):77-82 [11147798.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10987-97 [11790767.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):554-65 [12815381.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):420-5 [12901952.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32662-72 [12788955.001]
  • [Cites] Immunity. 2003 Nov;19(5):725-37 [14614859.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2185-95 [15141161.001]
  • [Cites] Nat Med. 2004 Oct;10(10):1128-32 [15448687.001]
  • [Cites] Drug News Perspect. 2004 Sep;17(7):447-53 [15514704.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17355-63 [2170374.001]
  • [Cites] Cell. 1994 Mar 25;76(6):1025-37 [8137421.001]
  • [Cites] J Mol Graph. 1994 Jun;12(2):98-105 [7918258.001]
  • [Cites] Genes Dev. 1994 Dec 15;8(24):2996-3007 [8001819.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2760-70 [8654373.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Jan;35(1-2):47-57 [8717339.001]
  • [Cites] J Mol Med (Berl). 1996 Oct;74(10):589-607 [8912180.001]
  • [Cites] Cell. 1996 Nov 29;87(5):929-39 [8945519.001]
  • [Cites] J Mol Biol. 1997 Apr 4;267(3):727-48 [9126849.001]
  • [Cites] Science. 1997 Aug 1;277(5326):693-6 [9235893.001]
  • [Cites] J Comput Aided Mol Des. 1997 Sep;11(5):425-45 [9385547.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 24;1333(2):F85-104 [9395283.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1740-9 [9501095.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):205-19 [9561845.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1671-4 [9733513.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36 [15722167.001]
  • [Cites] J Biol Chem. 2006 Jun 2;281(22):15258-67 [16571730.001]
  • [Cites] Anal Biochem. 2008 Jan 15;372(2):189-97 [17961489.001]
  • [Cites] Curr Mol Med. 2007 Nov;7(7):674-86 [18045145.001]
  • [Cites] J Med Chem. 2008 Jun 26;51(12):3460-5 [18494454.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):E18; author reply E19 [19204298.001]
  • (PMID = 18922779.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK073274; United States / NIDDK NIH HHS / DK / R24 DK080263; United States / NIDDK NIH HHS / DK / R21DK073274; United States / NIDDK NIH HHS / DK / R24DK080263
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-((5-nitro-2-thiazolyl)thio)-3H-1,2,4-triazol-3-one; 0 / Adaptor Proteins, Signal Transducing; 0 / Dioxanes; 0 / MAPK8IP1 protein, human; 0 / Protein Kinase Inhibitors; 0 / Thiazoles; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2567907
  •  go-up   go-down


2. Pan J, Qian J, Zhang Y, Ma J, Wang G, Xiao Q, Chen S, Ding J: Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway. Lab Invest; 2010 Feb;90(2):156-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sequence of Tat is corresponding to the cell-membrane transduction domain of human immunodeficiency virus-type 1 (HIV-1) and the sequence of an 11-amino acid peptide is corresponding to the residues of JNK-binding domain (JBD) on JNK-interacting protein-1 (JIP-1).
  • Tat-JBD is confirmed to perturb the assembly of JIP-1-JNKs complex, inhibit the activation of JNKs induced by MPTP and consequently diminish the phosphorylation of c-Jun.
  • Our findings imply that Tat-JBD offers neuroprotection against MPTP injury via inhibiting the JNK-signaling pathway, and may provide a promising therapeutic approach for PD.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / antagonists & inhibitors. JNK Mitogen-Activated Protein Kinases / drug effects. Neuroprotective Agents / therapeutic use. Parkinson Disease / drug therapy. Parkinson Disease / pathology. Peptides / therapeutic use
  • [MeSH-minor] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Animals. Apoptosis / drug effects. Disease Models, Animal. In Situ Nick-End Labeling. Male. Mice. Nerve Degeneration / prevention & control. Phosphorylation / drug effects. Protein Kinase Inhibitors. tat Gene Products, Human Immunodeficiency Virus / therapeutic use

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • Hazardous Substances Data Bank. 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010851.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Mapk8ip protein, mouse; 0 / Neuroprotective Agents; 0 / Peptides; 0 / Protein Kinase Inhibitors; 0 / Tat-JBD peptide; 0 / tat Gene Products, Human Immunodeficiency Virus; 9P21XSP91P / 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


3. Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Söderquist B: Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect; 2009 Mar;15(3):238-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene.
  • Staphylococcus epidermidis is the most important pathogen in infections related to implanted foreign materials, especially prosthetic joint infections (PJIs).
  • The aim of this study was to investigate the antimicrobial activities of 16 antibiotics against S. epidermidis isolated from PJIs, with special focus on rifampicin and rpoB variability.
  • Among the other antibiotics, the rates of resistance varied between 0% (vancomycin) and 82% (trimethoprim-sulphamethoxazole). S. epidermidis strains causing PJIs often show multiresistance, including resistance to rifampicin, which is mainly caused by one or two SNPs.
  • Some of the newer antimicrobial agents may provide alternatives for monotherapy or combination therapy with rifampicin.
  • Detection of mecA is necessary before initiating treatment of infections due to S. epidermidis when it displays intermediate susceptibility to cefoxitin.
  • [MeSH-major] Anti-Bacterial Agents / pharmacology. DNA-Directed RNA Polymerases / genetics. Drug Resistance, Bacterial. Prosthesis-Related Infections / microbiology. Rifampin / pharmacology. Staphylococcal Infections / microbiology. Staphylococcus epidermidis / drug effects
  • [MeSH-minor] Humans. Joint Prosthesis / adverse effects. Microbial Sensitivity Tests / methods

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19196261.001).
  • [ISSN] 1469-0691
  • [Journal-full-title] Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • [ISO-abbreviation] Clin. Microbiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; EC 2.7.7.6 / DNA-Directed RNA Polymerases; EC 2.7.7.6 / RNA polymerase beta subunit; VJT6J7R4TR / Rifampin
  •  go-up   go-down


Advertisement
4. Kuan CY, Burke RE: Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord; 2005 Feb;4(1):63-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy.
  • This unique property makes JNK signaling a promising target for developing pharmacological intervention.
  • The inhibitors of the JNK signaling pathway include upstream kinase inhibitors (for example, CEP-1347), small chemical inhibitors of JNK (SP600125 and AS601245), and peptide inhibitors of the interaction between JNK and its substrates (D-JNKI and I-JIP).
  • [MeSH-minor] Alzheimer Disease / drug therapy. Alzheimer Disease / enzymology. Animals. Cell Death / drug effects. Cell Death / physiology. Drug Design. Humans

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723614.001).
  • [ISSN] 1568-007X
  • [Journal-full-title] Current drug targets. CNS and neurological disorders
  • [ISO-abbreviation] Curr Drug Targets CNS Neurol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Number-of-references] 46
  •  go-up   go-down


5. Dong Z, Zhou L, Del Villar K, Ghanevati M, Tashjian V, Miller CA: JIP1 regulates neuronal apoptosis in response to stress. Brain Res Mol Brain Res; 2005 Apr 4;134(2):282-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, under certain stress conditions, down-regulation of JIP1 expression makes neurons more susceptible to apoptosis, suggesting JIP may serve as an anti-apoptosis factor.
  • [MeSH-minor] Animals. Animals, Newborn. Anoxia / drug therapy. Anoxia / metabolism. Blotting, Western / methods. Caspase 3. Caspases / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Enzyme Inhibitors / pharmacology. Hippocampus / cytology. Humans. Immunohistochemistry / methods. Indoles. MAP Kinase Kinase 7 / metabolism. Mice. Mitogen-Activated Protein Kinase 10 / metabolism. Neuroblastoma. Organ Culture Techniques. Proto-Oncogene Proteins c-jun / metabolism. Rats. Rats, Sprague-Dawley. Time Factors. Transfection / methods. Ultraviolet Rays / adverse effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15836924.001).
  • [ISSN] 0169-328X
  • [Journal-full-title] Brain research. Molecular brain research
  • [ISO-abbreviation] Brain Res. Mol. Brain Res.
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 5R37MH39145; United States / NINDS NIH HHS / NS / 5T32NS07149; United States / NIA NIH HHS / AG / AG05142; United States / NIA NIH HHS / AG / AG18879
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Enzyme Inhibitors; 0 / Indoles; 0 / MAPK8IP1 protein, human; 0 / Proto-Oncogene Proteins c-jun; 47165-04-8 / DAPI; EC 2.7.1.- / MAP2K7 protein, human; EC 2.7.1.- / Mitogen-Activated Protein Kinase 10; EC 2.7.12.2 / MAP Kinase Kinase 7; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


6. Parvizi J, Azzam K, Ghanem E, Austin MS, Rothman RH: Periprosthetic infection due to resistant staphylococci: serious problems on the horizon. Clin Orthop Relat Res; 2009 Jul;467(7):1732-9
MedlinePlus Health Information. consumer health - Staphylococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periprosthetic infection due to resistant staphylococci: serious problems on the horizon.
  • Prosthetic joint infections (PJI) caused by methicillin-resistant staphylococci represent a major therapeutic challenge.
  • We examined the effectiveness of surgical treatment in treating infection of total hip or knee arthroplasty caused by methicillin-resistant staphylococcal strains and the variables influencing treatment success.
  • Patients were followed for a minimum of 2 years or until recurrence of infection.
  • Débridement controlled the infection in only 37% of cases whereas two-stage exchange arthroplasty controlled the infection in 75% of hips and 60% of knees.
  • Preexisting cardiac disease was associated with a higher likelihood of failure to control infection in all treatment groups.
  • Antibiotic-resistant Staphylococci continue to compromise treatment outcome of prosthetic joint infections, especially in patients with medical comorbidities.
  • New preventive and therapeutic strategies are needed.
  • LEVEL OF EVIDENCE: Level IV, therapeutic study.
  • [MeSH-major] Methicillin-Resistant Staphylococcus aureus. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / surgery. Staphylococcal Infections / drug therapy. Staphylococcal Infections / surgery
  • [MeSH-minor] Aged. Arthroplasty, Replacement, Hip / statistics & numerical data. Arthroplasty, Replacement, Knee / statistics & numerical data. Combined Modality Therapy. Comorbidity. Debridement / statistics & numerical data. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recurrence. Reoperation. Risk Factors

  • MedlinePlus Health Information. consumer health - MRSA.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):16-22 [12360002.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):23-8 [12360003.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):116-24 [12439249.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] Chir Organi Mov. 1994 Oct-Dec;79(4):285-91 [7614867.001]
  • [Cites] J Arthroplasty. 1998 Jan;13(1):22-8 [9493534.001]
  • [Cites] Clin Orthop Relat Res. 2007 Aug;461:48-53 [17534195.001]
  • [Cites] Am J Infect Control. 2004 Dec;32(8):470-85 [15573054.001]
  • [Cites] J Orthop Surg (Hong Kong). 2005 Aug;13(2):125-30 [16131673.001]
  • [Cites] J Bone Joint Surg Am. 2006 Jun;88(6):1231-7 [16757755.001]
  • [Cites] Am J Med. 2006 Nov;119(11):993.e7-10 [17071171.001]
  • [Cites] Clin Microbiol Infect. 2007 Jun;13(6):586-91 [17331125.001]
  • [Cites] J Bone Joint Surg Am. 2007 Jun;89(6):1227-31 [17545425.001]
  • [Cites] Clin Orthop Relat Res. 2004 Oct;(427):94-100 [15552143.001]
  • (PMID = 19408061.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2690767
  •  go-up   go-down


7. Tóth K, Janositz G, Kovács G, Sisák K, Rudner E: Successful treatment of late Salmonella infections in total hip replacement - report of two cases. BMC Infect Dis; 2010;10:160
Hazardous Substances Data Bank. CIPROFLOXACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of late Salmonella infections in total hip replacement - report of two cases.
  • BACKGROUND: Salmonella species can be rarely isolated from periprosthetic joint infections, however when present, are usually part of a severe septic clinical picture.
  • The first patient with multiple comorbidities had a confirmed Salmonella Enteridis infection with an abscess in the groin, with loosening of both components.
  • He underwent a successful one stage cemented revision hip replacement, followed by 6 weeks of antibiotic therapy (ciprofloxacin).
  • CONCLUSIONS: Successful treatment of such potentially life threatening infections is achievable using modern orthopaedic techniques and close collaboration with the infectious diseases specialists.
  • [MeSH-major] Arthroplasty, Replacement, Hip. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / surgery. Salmonella Infections / diagnosis. Salmonella arizonae / isolation & purification. Salmonella enteritidis / isolation & purification
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Ciprofloxacin / therapeutic use. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • MedlinePlus Health Information. consumer health - Salmonella Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Trop Paediatr. 2001 Mar;21(1):88-90 [11284255.001]
  • [Cites] Acta Orthop Scand. 1967;38(2):220-5 [6033415.001]
  • [Cites] J Infect Dis. 1978 Dec;138(6):820-8 [368264.001]
  • [Cites] Clin Orthop Relat Res. 1978 Nov-Dec;(137):69-75 [743846.001]
  • [Cites] Arch Orthop Trauma Surg. 1982;99(4):281-3 [7092526.001]
  • [Cites] Rev Infect Dis. 1986 Nov-Dec;8(6):978-83 [3541130.001]
  • [Cites] Jpn J Infect Dis. 2005 Feb;58(1):29-30 [15728987.001]
  • [Cites] Scand J Infect Dis. 1990;22(5):611-8 [2259871.001]
  • [Cites] Clin Infect Dis. 1992 Jun;14(6):1251-3 [1623081.001]
  • [Cites] J Bone Joint Surg Am. 1996 Apr;78(4):512-23 [8609130.001]
  • [Cites] Br J Rheumatol. 1997 Mar;36(3):370-3 [9133971.001]
  • [Cites] Clin Infect Dis. 1997 May;24(5):914-9 [9142792.001]
  • [Cites] Int Orthop. 1990;14(2):161-5 [2197238.001]
  • (PMID = 20529326.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 5E8K9I0O4U / Ciprofloxacin
  • [Other-IDs] NLM/ PMC2894836
  •  go-up   go-down


8. Bejon P, Berendt A, Atkins BL, Green N, Parry H, Masters S, McLardy-Smith P, Gundle R, Byren I: Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology. J Antimicrob Chemother; 2010 Mar;65(3):569-75
MedlinePlus Health Information. consumer health - Joint Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology.
  • OBJECTIVES: We describe rates of success for two-stage revision of prosthetic joint infection (PJI), including data on reimplantation microbiology.
  • METHODS: We retrospectively collected data from all the cases of PJI that were managed with two-stage revision over a 4 year period.
  • Patients were managed with an antibiotic-free period before reimplantation, in order to confirm, clinically and microbiologically, that infection was successfully treated.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Joint Diseases / drug therapy. Joint Diseases / surgery. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / surgery. Replantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2000 Nov;82-A(11):1552-7 [11097443.001]
  • [Cites] J Arthroplasty. 1998 Jan;13(1):22-8 [9493534.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] J Bone Joint Surg Am. 2003 Jan;85-A(1):20-6 [12533567.001]
  • [Cites] Infection. 2003 Mar;31(2):99-108 [12682815.001]
  • [Cites] J Bone Joint Surg Am. 2004 May;86-A(5):963-74 [15118039.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jun;(117):221-40 [776484.001]
  • [Cites] N Engl J Med. 1992 Jan 30;326(5):281-6 [1728731.001]
  • [Cites] Clin Orthop Relat Res. 1995 Dec;(321):55-67 [7497686.001]
  • [Cites] J Bone Joint Surg Am. 1995 Dec;77(12):1807-13 [8550647.001]
  • [Cites] JAMA. 1996 Mar 20;275(11):858-65 [8596224.001]
  • [Cites] Clin Orthop Relat Res. 1997 May;(338):192-204 [9170380.001]
  • [Cites] Clin Orthop Relat Res. 1997 Dec;(345):134-9 [9418630.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10):2932-9 [9738046.001]
  • [Cites] J Bone Joint Surg Am. 1999 May;81(5):672-83 [10360695.001]
  • [Cites] J Arthroplasty. 2005 Dec;20(8):1037-41 [16376260.001]
  • [Cites] J Clin Microbiol. 2006 Feb;44(2):628-31 [16455930.001]
  • [Cites] J Arthroplasty. 2007 Jan;22(1):72-8 [17197311.001]
  • [Cites] J Bone Joint Surg Am. 2007 Jun;89(6):1227-31 [17545425.001]
  • [Cites] J Infect. 2007 Jul;55(1):1-7 [17343916.001]
  • [Cites] J Antimicrob Chemother. 2007 Aug;60(2):356-62 [17566002.001]
  • [Cites] J Bone Joint Surg Br. 2007 Aug;89(8):1010-4 [17785736.001]
  • [Cites] Clin Infect Dis. 2007 Nov 1;45(9):1113-9 [17918072.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2008 Sep;27(9):805-11 [18431606.001]
  • [Cites] Clin Infect Dis. 2008 Dec 1;47(11):1403-9 [18937579.001]
  • [Cites] Clin Orthop Relat Res. 2009 Jan;467(1):219-24 [18813895.001]
  • [Cites] J Bone Joint Surg Br. 2009 Jan;91(1):44-51 [19092003.001]
  • [Cites] Acta Orthop. 2009 Feb;80(1):67-77 [19234888.001]
  • [Cites] J Antimicrob Chemother. 2009 Jun;63(6):1264-71 [19336454.001]
  • [Cites] PLoS Med. 2008 Sep 30;5(9):e179 [18767900.001]
  • [Cites] J Antimicrob Chemother. 2009 Aug;64(2):392-7 [19477889.001]
  • [ErratumIn] J Antimicrob Chemother. 2011 May;66(5):1204
  • (PMID = 20053693.001).
  • [ISSN] 1460-2091
  • [Journal-full-title] The Journal of antimicrobial chemotherapy
  • [ISO-abbreviation] J. Antimicrob. Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC2818105
  •  go-up   go-down


9. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, Yamaue H: Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol; 2006 May 1;93(6):485-90
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
  • In our study, we investigated whether postoperative chemotherapy improved survival in patients with invasive ductal carcinoma of the pancreas.
  • Median survival time (MST) was 19.4 months, 8.6 months, and 7.2 months, in JPS Stage III (UICC Stage IIA and IIB), JPS Stage IVa (UICC Stage IIA and IIB), and JPS Stage IVb (UICC Stage IV), respectively (P < 0.01).
  • The MST of the chemotherapy group was 12 months, and the MST of the non-chemotherapy group was 8.4 months (P < 0.05).
  • Moreover, in JPS Stage IV (UICC Stage IIA, IIB, III, and IV) highly advanced pancreatic cancer, the MST of the chemotherapy group was 10.9 months, and the MST of the group without chemotherapy was 6.6 months (P < 0.01).
  • Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Pancreatectomy / mortality. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16615151.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Motycka V, Sákra L, Mencl K, Havlícek K: [Occurrence of yeast infections at a surgical intensive care unit]. Rozhl Chir; 2001 Jun;80(6):320-3
MedlinePlus Health Information. consumer health - Yeast Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occurrence of yeast infections at a surgical intensive care unit].
  • [Transliterated title] Výskyt kvasinkových infekcí na chirurgické JIP.
  • The authors evaluate the occurrence of candida infections in the surgical intensive care unit (ICU) in a one-year period.
  • From the group of 1798 patients hospitalized in a surgical ICU there are 50 patients (2.8%) with candida colonisation and even 56 patients (3.1%) with candida infection.
  • The authors evaluate risk factors for development of candida infection, its etiologic agents and the most frequent site of infection.
  • In addition to usual treatment the authors suggest pre-emptive therapy in patients with risk factors.
  • In the one-year period, two patients died of multiorgan failure (MOF) in close connection with candida infection (sepsis).
  • The mortality of the group with proved candida infection was 3.57%.
  • [MeSH-major] Candidiasis. Cross Infection
  • [MeSH-minor] Humans. Intensive Care Units. Mycoses / diagnosis. Mycoses / drug therapy. Mycoses / transmission. Retrospective Studies. Risk Factors. Trichosporon

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11482157.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


11. Parvizi J, Pawasarat IM, Azzam KA, Joshi A, Hansen EN, Bozic KJ: Periprosthetic joint infection: the economic impact of methicillin-resistant infections. J Arthroplasty; 2010 Sep;25(6 Suppl):103-7
Hazardous Substances Data Bank. METHICILLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periprosthetic joint infection: the economic impact of methicillin-resistant infections.
  • The orthopedic community has begun to witness a worrisome rise in the incidence of periprosthetic joint infections (PJIs) caused by resistant organisms.
  • Besides other challenges associated with treating these infections, it appears that these infections may pose a higher cost compared to infections caused by sensitive organisms.
  • Significantly higher cost of care for treatment of infections due to methicillin-resistant organisms were seen at a mean of $107,264 per case compared to $68,053 for treating PJI caused by sensitive strains (P < .0001).
  • More effective strategies for preventing the spread of infections caused by resistant organisms need to be implemented to ease the social and economic strains facing the orthopedic community due to resistant organisms.
  • [MeSH-major] Hospital Costs / trends. Methicillin Resistance. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / economics. Staphylococcal Infections / drug therapy. Staphylococcal Infections / economics
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Arthroplasty, Replacement, Hip / instrumentation. Arthroplasty, Replacement, Knee / instrumentation. Female. Hip Prosthesis / microbiology. Humans. Incidence. Knee Prosthesis / microbiology. Male. Methicillin / therapeutic use. Middle Aged. Retrospective Studies. Staphylococcus aureus / isolation & purification. Staphylococcus epidermidis / isolation & purification

  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20570103.001).
  • [ISSN] 1532-8406
  • [Journal-full-title] The Journal of arthroplasty
  • [ISO-abbreviation] J Arthroplasty
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; Q91FH1328A / Methicillin
  •  go-up   go-down


12. Sobiś J, Jarzab M, Hese RT, Sieroń A, Zyss T, Gorczyca P, Gierlotka Z, Pudlo R, Matysiakiewicz J: Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression. J Affect Disord; 2010 Jun;123(1-3):321-6
Genetic Alliance. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression.
  • BACKGROUND: The aim of this prospective study was to verify whether magnetostimulation with weak variable magnetic fields with low value of induction could enhance the effects of pharmacological therapy in drug-resistant depression.
  • MATERIALS AND METHODS: Thirty patients, 26 women and 4 men, with drug-resistant depression were enrolled in the study.
  • I (14 patients) were given fluvoxamine and treated with weak variable magnetic field using the VIOFOR JPS device; the subjects from Group No.
  • II (16 patients) were also given fluvoxamine but they were treated with the VIOFOR JPS device in placebo mode.
  • RESULTS: After 15 days of treatment highly significant differences were revealed between the patients treated with magnetic field and the patients treated with placebo: the final HDRS score was 53% of the initial value for the group receiving combined treatment, and 86% in the placebo group (p<0.001); for MADRS score the values were 51% and 88% (p<0.001), respectively, and for BDI 60% and 87% (p<0.001).
  • 15% reduction of symptoms, while the concurrent application of magnetic field and SSRI treatment resulted in a 40-50% improvement.
  • CONCLUSION: Our study indicates that adding a two-week low-induction variable magnetic field stimulation to a classical pharmacologic therapy reduces the intensity of symptoms in patients with drug-resistant depressive disorders.
  • [MeSH-major] Antidepressive Agents, Second-Generation / therapeutic use. Depressive Disorder, Major / therapy. Fluvoxamine / therapeutic use. Transcranial Magnetic Stimulation / methods
  • [MeSH-minor] Adult. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance. Female. Humans. Male. Middle Aged. Personality Inventory. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19896204.001).
  • [ISSN] 1573-2517
  • [Journal-full-title] Journal of affective disorders
  • [ISO-abbreviation] J Affect Disord
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; O4L1XPO44W / Fluvoxamine
  •  go-up   go-down


13. Parvizi J, Matar WY, Saleh KJ, Schmalzried TP, Mihalko WM: Decolonization of drug-resistant organisms before total joint arthroplasty. Instr Course Lect; 2010;59:131-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decolonization of drug-resistant organisms before total joint arthroplasty.
  • Periprosthetic joint infection is now the leading cause of failure after a total knee arthroplasty, and Staphylococcus aureus, most commonly from the patient's own flora, typically is the infective agent.
  • Several preoperative screening tests have been developed to identify patients who are carrying methicillin-resistant S aureus.
  • Testing and decolonization programs have generally been effective in decreasing the incidence of surgical site infections, but the role of such programs in total joint arthroplasty has not been thoroughly investigated.
  • Although recent studies found a tendency toward fewer methicillin-resistant S aureus infections after total joint arthroplasty when a testing and decolonization program was used, most of these studies were underpowered.
  • [MeSH-major] Antibiotic Prophylaxis. Arthroplasty, Replacement, Knee. Carrier State / therapy. Methicillin-Resistant Staphylococcus aureus. Staphylococcal Infections / prevention & control. Surgical Wound Infection / prevention & control
  • [MeSH-minor] Drug Resistance, Microbial. Humans. Preoperative Care

  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • MedlinePlus Health Information. consumer health - MRSA.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415376.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. You JH, Lee GC, So RK, Cheung KW, Hui M: Linezolid versus vancomycin for prosthetic joint infections: a cost analysis. Infection; 2007 Jun;35(4):265-70
Hazardous Substances Data Bank. LINEZOLID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linezolid versus vancomycin for prosthetic joint infections: a cost analysis.
  • BACKGROUND: Prosthetic joint infections (PJIs) caused by methicillin-resistant gram-positive bacteria are primarily treated by intravenous vancomycin.
  • Linezolid, active against methicillin-resistant strains and available in oral and intravenous dosage forms, is a potential alternative to vancomycin for the treatment of PJIs.
  • OBJECTIVE: To analyze the cost of linezolid therapy (outpatient setting) and vancomycin therapy (inpatient and outpatient settings) for PJIs caused by methicillin-resistant gram-positive bacteria.
  • METHODS: A decision tree was designed to simulate the clinical outcome and healthcare resource utilization of linezolid, vancomycin by outpatient and home parenteral antimicrobial therapies (OHPAT) and vancomycin administered in inpatient setting (rehabilitation facility) for patients with PJIs caused by methicillin-resistant strains.
  • The clinical treatment success rates of vancomycin and linezolid were influential factors.
  • Monte Carlo 10,000 simulations showed that the vancomycin (OHPAT) group was less costly than the arms of linezolid and vancomycin (rehabilitation) 64% and 100% of the time, respectively.
  • The linezolid group was less costly than the vancomycin (rehabilitation) group in 65%of the times.
  • CONCLUSION: Home-infusion of vancomycin therapy appears to be the least costly treatment approach for PJIs caused by methicillin-resistant gram-positive bacteria from the perspective of a Hong Kong public health organization.
  • [MeSH-major] Acetamides. Anti-Bacterial Agents. Health Care Costs / statistics & numerical data. Oxazolidinones. Prosthesis-Related Infections. Vancomycin
  • [MeSH-minor] Administration, Oral. Algorithms. Costs and Cost Analysis. Gram-Positive Bacterial Infections / drug therapy. Gram-Positive Bacterial Infections / economics. Home Care Services / economics. Humans. Infusions, Intravenous / economics. Joint Prosthesis / microbiology. Linezolid. Methicillin Resistance / genetics

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646907.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acetamides; 0 / Anti-Bacterial Agents; 0 / Oxazolidinones; 6Q205EH1VU / Vancomycin; ISQ9I6J12J / Linezolid
  •  go-up   go-down


15. Moran E, Masters S, Berendt AR, McLardy-Smith P, Byren I, Atkins BL: Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect; 2007 Jul;55(1):1-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention.
  • OBJECTIVES: This study describes the microbiological spectrum of prosthetic joint infection (PJI) managed by debridement, washout and retention and so guides the choice of empirical antibiotics within this patient group.
  • METHODS: We performed a retrospective review of all patients admitted to our specialist tertiary unit for PJI who were managed with debridement and irrigation or arthroscopic washout of infected prosthetic joints between 1st January 1998 and 30th April 2003.
  • Eighty-six percent of polymicrobial cultures occurred in early infections when 47% of patients grew more than one organism.
  • MSSA was the most frequently isolated organism at all time points.
  • CONCLUSIONS: Most infections involved staphylococci.
  • Most polymicrobial infections occurred in early infection.
  • A high rate of resistance to cephalosporins among Gram-negative organisms justifies the use of a broader agent such as a carbapenem in the early empirical antibiotic regime for PJI.
  • [MeSH-major] Anti-Bacterial Agents. Arthroplasty, Replacement / adverse effects. Gram-Negative Bacteria / drug effects. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / drug therapy. Staphylococcus / drug effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Debridement. Female. Gram-Negative Bacterial Infections / drug therapy. Gram-Negative Bacterial Infections / microbiology. Hip Prosthesis / adverse effects. Humans. Knee Prosthesis / adverse effects. Male. Microbial Sensitivity Tests. Middle Aged. Staphylococcal Infections / microbiology. Staphylococcus aureus / drug effects. Staphylococcus aureus / isolation & purification. Therapeutic Irrigation

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343916.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


16. Bernard L, Legout L, Zürcher-Pfund L, Stern R, Rohner P, Peter R, Assal M, Lew D, Hoffmeyer P, Uçkay I: Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty. J Infect; 2010 Jul;61(2):125-32
MedlinePlus Health Information. consumer health - Infectious Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty.
  • OBJECTIVES: In the treatment of prosthetic joint infections (PJI), the benefit of antibiotic therapy for more than 6 weeks after surgery is uncertain.
  • We compared PJI cure rates according to the duration of antibiotics, 6 versus 12 weeks.
  • RESULTS: A total of 144 PJI (62 hip arthroplasties, 62 knee arthroplasties, and 20 hip hemiarthroplasties) were included with a prolonged follow-up ranging from 26 to 65 months.
  • Surgical treatment included 60 débridements with implant retention, 10 one-stage exchanges of the prosthesis, 57 two-stage exchanges, and 17 Girdlestone procedures or knee arthrodeses.
  • Seventy episodes (49%) received 6 weeks antibiotic therapy and 74 episodes, 12 weeks.
  • In multivariate analysis, none of the following parameters was statistically significantly associated with cure: two-stage exchange (odds ratio 1.1,95%CI 0.2-4.8); number of débridements (0.9, 0.4-1.9); six weeks antibiotherapy (2.7, 0.96-8.3); duration of intravenous course (1.0, 0.96-1.03); sinus tract (0.6, 0.2-1.7); or MRSA infection (0.5, 0.2-1.5), although implant retention showed a tendency for less cure (0.3, 0.1-1.1).
  • CONCLUSIONS: Following surgery for treatment of PJI, antibiotic therapy appears able to be limited to a 6-week course, with one week of intravenous administration.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Arthritis, Infectious / surgery. Arthroplasty. Bacterial Infections / drug therapy. Prosthesis-Related Infections / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Debridement. Female. Follow-Up Studies. Humans. Male. Prospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540962.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


17. Anguita-Alonso P, Hanssen AD, Osmon DR, Trampuz A, Steckelberg JM, Patel R: High rate of aminoglycoside resistance among staphylococci causing prosthetic joint infection. Clin Orthop Relat Res; 2005 Oct;439:43-7
Hazardous Substances Data Bank. TOBRAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rate of aminoglycoside resistance among staphylococci causing prosthetic joint infection.
  • Gentamicin and tobramycin are two aminoglycosides commonly impregnated into polymethylmethacrylate for treatment and prevention of prosthetic joint infection.
  • The gentamicin and tobramycin minimum inhibitory value of 93 staphylococci from patients with PJI were determined.
  • The findings suggest that consideration should be given to the further study of agents other than aminoglycosides for incorporation into polymethylmethacrylate for the treatment and prevention of prosthetic joint infection.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Gentamicins / therapeutic use. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / microbiology. Staphylococcal Infections / drug therapy. Staphylococcus aureus / drug effects
  • [MeSH-minor] Bone Cements. Drug Resistance, Multiple, Bacterial. Humans. Methicillin Resistance. Polymethyl Methacrylate. Prostheses and Implants / microbiology. Tobramycin / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205136.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bone Cements; 0 / Gentamicins; 9011-14-7 / Polymethyl Methacrylate; VZ8RRZ51VK / Tobramycin
  •  go-up   go-down


18. Schäfer P, Fink B, Sandow D, Margull A, Berger I, Frommelt L: Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. Clin Infect Dis; 2008 Dec 1;47(11):1403-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy.
  • BACKGROUND: The value of microbiological culture to diagnose late periprosthetic infection is limited, especially because standard methods may fail to detect biofilm-forming sessile or other fastidious bacteria.
  • This study was designed to assess the duration of culture that is necessary for reliable detection.
  • PATIENTS AND METHODS: Ten periprosthetic tissue specimens each were obtained during revision from 284 patients with suspected late hip or knee arthroplasty infection.
  • To define infection, a pre-established algorithm was used; this included detection of indistinguishable organisms in >/=2 tissue samples or growth in 1 tissue sample and a positive result of histologic analysis (>5 neutrophils in at least 10 high-power fields).
  • The time to detection of organisms was monitored.
  • RESULTS: Infection was diagnosed in 110 patients.
  • After 7 days (the longest incubation period most frequently reported), the detection rate via culture was merely 73.6%.
  • Organisms indicating infection were found for up to 13 days.
  • In both populations, an unequivocal correlation between the number of culture-positive tissue samples and positive results of histologic analysis was noted, which corroborated the evidence that true infections were detected over the entire cultivation period.
  • CONCLUSIONS: Prolonged microbiological culture for 2 weeks is promising because it yields signs of periprosthetic infection in a significant proportion of patients that would otherwise remain unidentified.
  • [MeSH-major] Arthritis / diagnosis. Bacterial Infections / diagnosis. Bacteriological Techniques. Hip / microbiology. Knee / microbiology. Prosthesis-Related Infections / diagnosis
  • [MeSH-minor] Aged. Bacteria / isolation & purification. Female. Humans. Male. Statistics as Topic. Time Factors


19. Rao N, Regalla DM: Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res; 2006 Oct;451:34-7
MedlinePlus Health Information. consumer health - Staphylococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series.
  • Daptomycin is an option for prosthetic joint infection (PJI) because it is bactericidal against gram-positive bacteria, including multiple-resistant isolates, and active against stationary-phase bacteria in biofilm present on implants.
  • To evaluate its possible utility, we prospectively monitored 12 adults with gram-positive PJI who were not candidates for vancomycin.
  • One died of an unrelated cause shortly after completing therapy.
  • Five patients had culture-confirmed failure-all due to MRSA-including two during therapy despite hardware removal and three 1 to 10 months after completing daptomycin but with retained hardware.
  • The efficacy of daptomycin 4 mg/kg/day is uncertain in patients with PJI, especially when hardware is retained.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Arthroplasty, Replacement / adverse effects. Daptomycin / therapeutic use. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / drug therapy. Staphylococcal Infections / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735866.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; NWQ5N31VKK / Daptomycin
  •  go-up   go-down


20. Hazneci B, Tan AK, Guncikan MN, Dincer K, Kalyon TA: Comparison of the efficacies of botulinum toxin A and Johnstone pressure splints against hip adductor spasticity among patients with cerebral palsy: a randomized trial. Mil Med; 2006 Jul;171(7):653-6
MedlinePlus Health Information. consumer health - Cerebral Palsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The goal was to compare the efficacies of botulinum toxin A (BTX) treatment and Johnstone pressure splint (JPS) treatment against hip adductor muscle spasticity among children with spastic diplegic cerebral palsy.
  • In the JPS group, long leg JPS were administered for 30 minutes 3 days per week.
  • BTX treatment was found to be superior to JPS treatment in terms of the indicator variables of our study.
  • [MeSH-major] Botulinum Toxins, Type A / therapeutic use. Cerebral Palsy / physiopathology. Hip Joint / physiopathology. Muscle Spasticity / drug therapy. Splints
  • [MeSH-minor] Adolescent. Child. Humans. Muscle, Skeletal / drug effects. Muscle, Skeletal / physiopathology. Range of Motion, Articular. Treatment Outcome

  • Genetic Alliance. consumer health - Cerebral Palsy.
  • Genetic Alliance. consumer health - Spasticity.
  • MedlinePlus Health Information. consumer health - Botox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16895135.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


21. Han SH, Lee DB, Lee DW, Kim EH, Yoon BS: Ultra-rapid real-time PCR for the detection of Paenibacillus larvae, the causative agent of American Foulbrood (AFB). J Invertebr Pathol; 2008 Sep;99(1):8-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultra-rapid real-time PCR for the detection of Paenibacillus larvae, the causative agent of American Foulbrood (AFB).
  • A novel micro-PCR-based detection method, termed ultra-rapid real-time PCR, was applied to the development of a rapid detection for Paenibacillus larvae (P. larvae) which is the causative agent of American Foulbrood (AFB).
  • This method was designed to detect the 16S rRNA gene of P. larvae with a micro-scale chip-based real-time PCR system, GenSpector TMC-1000, which has uncommonly fast heating and cooling rates (10 degrees C per second) and small reaction volume (6microl).
  • In the application of ultra-rapid real-time PCR detection to an AFB-infected larva, the minimum detection time was 7 min and 54s total reaction time (30 cycles), including the melting temperature analysis.
  • To the best of our knowledge, this novel detection method is one of the most rapid real-time PCR-based detection tools.
  • [MeSH-major] Bacillaceae / isolation & purification. Bees / microbiology. Gram-Positive Bacterial Infections / veterinary. Polymerase Chain Reaction / methods
  • [MeSH-minor] Animals. DNA, Bacterial / analysis. Host-Pathogen Interactions. Larva / microbiology. Reproducibility of Results. Sensitivity and Specificity. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18571197.001).
  • [ISSN] 1096-0805
  • [Journal-full-title] Journal of invertebrate pathology
  • [ISO-abbreviation] J. Invertebr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial
  •  go-up   go-down


22. Sieroń A, Hese RT, Sobiś J, Cieślar G: [Estimation of therapeutical efficacy of weak variable magnetic fields with low value of induction in patients with depression]. Psychiatr Pol; 2004 Mar-Apr;38(2):217-25
Hazardous Substances Data Bank. PAROXETINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Preliminary results of research on the therapeutical efficacy of weak variable magnetic fields with low value of induction used as magnetostimulation in patients with depression not reacting to two consecutive, correctly applied anti-depressant pharmacological treatment are presented in the paper.
  • In 1 group (11 persons--9 women and 2 men) magnetostimulation with the use of a weak variable magnetic field with a low value of induction of 15 microT generated by the VIOFOR JPS device (Poland) lasting 12 minutes daily for 15 days was added to pharmacological therapy.
  • CONCLUSIONS: It was concluded that adding magnetostimulation to pharmacological therapy results in a progressive, significant reduction of intensification of depression symptoms.
  • [MeSH-major] Antidepressive Agents, Second-Generation / administration & dosage. Depressive Disorder / physiopathology. Depressive Disorder / therapy. Magnetics / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Electromagnetic Fields. Female. Fluvoxamine / administration & dosage. Humans. Male. Middle Aged. Paroxetine / administration & dosage. Severity of Illness Index. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15307288.001).
  • [ISSN] 0033-2674
  • [Journal-full-title] Psychiatria polska
  • [ISO-abbreviation] Psychiatr. Pol.
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; 41VRH5220H / Paroxetine; O4L1XPO44W / Fluvoxamine
  •  go-up   go-down


23. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas; 2004 Apr;28(3):219-30
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative histologic diagnosis and diagnostic imaging are fundamentals in managing the disease, but it is not rare to find unexpected peritoneal dissemination or liver metastasis at the time of operation.
  • Multidisciplinary treatments combined with surgery were performed, and various effects of postoperative chemotherapy after pancreatectomy, intraoperative- and postoperative-radiation therapy, or postoperative chemotherapy for unresectable tumor, were shown.
  • Development of unconventional therapies and refinement of the conventional therapy should be promoted on a randomized prospective trial basis.
  • To promote this effort, which requires the international comparisons and cooperation, JPS developed a computerized JPS registration system downloadable from the JPS website (http://www.kojin.or.jp/suizou/index.html).
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Registries
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084961.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. El Helou OC, Berbari EF, Lahr BD, Eckel-Passow JE, Razonable RR, Sia IG, Virk A, Walker RC, Steckelberg JM, Wilson WR, Hanssen AD, Osmon DR: Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis; 2010 Aug;29(8):961-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.
  • The aim of this study was to evaluate the efficacy and safety of rifampin for Staphylococcus aureus (SA) or coagulase negative staphylococci (CNS) prosthetic joint infection (PJI) treated with debridement and retention (D/R).
  • We calculated the treatment failure cumulative incidence (TF) of a cohort of 101 patients with SA or CNS PJI treated with D/R and antimicrobial therapy.
  • Cox proportional hazards regression evaluated the association between treatment and time-to-TF controlling for the propensity to treat with rifampin and temporal confounders.
  • Seven percent (1/14) of the prospective rifampin-treated patients, 32% (10/31) of the historical rifampin-treated patients and 38% (21/56) of the historical non-rifampin treated patients developed TF.
  • None (0/14) of the patients in the prospective study developed hepatotoxicity.
  • The outcome of staphylococcal PJI treated with D/R and rifampin-based regimens was better when compared with a historical cohort treated without rifampin.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Prosthesis-Related Infections / drug therapy. Rifampin / administration & dosage. Staphylococcal Infections / drug therapy. Staphylococcus / isolation & purification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Debridement. Female. Humans. Liver / drug effects. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2007 Nov 1;45(9):1113-9 [17918072.001]
  • [Cites] Sci Am. 1981 Oct;245(4):54-63 [7027437.001]
  • [Cites] Clin Infect Dis. 2006 Jan 15;42(2):216-23 [16355332.001]
  • [Cites] Clin Microbiol Infect. 2006 Sep;12(9):930-3 [16882303.001]
  • [Cites] Infection. 2004 Aug;32(4):222-8 [15293078.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12 Suppl 3:93-101 [16669932.001]
  • [Cites] J Bone Joint Surg Am. 2007 Mar;89(3):526-33 [17332101.001]
  • [Cites] Clin Microbiol Infect. 2007 Jun;13(6):586-91 [17331125.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Dec;50(12):4011-7 [17015630.001]
  • [Cites] Orthopedics. 1991 Aug;14(8):841-4 [1923965.001]
  • [Cites] Injury. 2006 May;37 Suppl 2:S3-14 [16651069.001]
  • [Cites] J Antimicrob Chemother. 2001 Aug;48(2):253-8 [11481297.001]
  • [Cites] J Antimicrob Chemother. 1997 Feb;39(2):235-40 [9069545.001]
  • [Cites] Lancet. 2001 Jul 14;358(9276):135-8 [11463434.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):471-8 [16421790.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):419-30 [11170950.001]
  • [Cites] Acta Orthop. 2007 Dec;78(6):755-65 [18236181.001]
  • [Cites] Am J Med. 2006 Nov;119(11):993.e7-10 [17071171.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1285-92 [15494904.001]
  • [Cites] Mater Manag Health Care. 2006 Jul;15(7):61-2 [16900875.001]
  • (PMID = 20505968.001).
  • [ISSN] 1435-4373
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; VJT6J7R4TR / Rifampin
  •  go-up   go-down


25. Sousa R, Pereira A, Massada M, da Silva MV, Lemos R, Costa e Castro J: Empirical antibiotic therapy in prosthetic joint infections. Acta Orthop Belg; 2010 Apr;76(2):254-9
Hazardous Substances Data Bank. Vancomycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Empirical antibiotic therapy in prosthetic joint infections.
  • When dealing with prosthetic joint infections (PJI) there is often the need to start antibiotic therapy without having identified the underlying pathogen.
  • We aimed to produce local recommendations for empirical antibiotic treatment of PJI by describing the microbiological spectrum involved and respective antibiotic susceptibility profile.
  • We examined the records of 75 consecutive patients that underwent surgery for prosthetic joint infection from July 2001 to December 2008.
  • Staphylococcus sp. was present in most infections (72.8%) regardless of surgical site or classification.
  • Gram negative pathogens were present in about 15% of all cases, especially in haematogenous and chronic infections.
  • Our results suggest that in acute post-operative infections, treatment should start with vancomycin.
  • In chronic and haematogeneous infections, vancomycin in combination with carbapenems appears to be an effective regimen.
  • Treatment should be adjusted as soon as preliminary or definitive microbiology results are available.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / microbiology

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20503953.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 6Q205EH1VU / Vancomycin
  •  go-up   go-down


26. Lorusso M, Mangiantini F, Pozzi E, Nucci A, Bronzini F, Bevilacqua S, Lionetti P: [Efficacy of meloxicam in juvenile polyposis syndrome. A case report]. Pediatr Med Chir; 2009 Mar-Apr;31(2):86-8
Hazardous Substances Data Bank. Meloxicam .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of meloxicam in juvenile polyposis syndrome. A case report].
  • [Transliterated title] Poliposi giovanile in un caso clinico in cui e risultata efficace la terapia con meloxicam.
  • The Authors present a case of a 11 year-old patient with a history of Juvenile Polyposis Syndrome (JPS), a condition characterized by the occurrence of multiple hamartomatous polyps in the gastrointestinal tract.
  • Patients with JPS are traditionally treated by repeated endoscopic polypectomies and elective surgery.
  • Recent studies reported up-regulation of cyclo-ossigenase 2 (COX-2) in colorectal polyps.
  • However efficacy and safety of preferential selective COX-2 inhibitor has been reported as antiinflammatory drugs also in children.
  • In this patient meloxicam treatment, a preferential selective COX-2 inhibitor, leaded to a significant reduction in the number of colorectal polyps during 3 years follow up.
  • [MeSH-major] Colonic Polyps / diagnosis. Colonic Polyps / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Thiazines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Adenomatous Polyposis Coli / diagnosis. Child. Diagnosis, Differential. Female. Humans. Syndrome. Treatment Outcome

  • Genetic Alliance. consumer health - Juvenile polyposis syndrome.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642502.001).
  • [ISSN] 0391-5387
  • [Journal-full-title] La Pediatria medica e chirurgica : Medical and surgical pediatrics
  • [ISO-abbreviation] Pediatr Med Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Thiazines; 0 / Thiazoles; 71125-38-7 / meloxicam
  •  go-up   go-down


27. Shuford JA, Piper KE, Hein M, Trampuz A, Steckelberg JM, Patel R: Lack of association of Staphylococcus aureus type A beta-lactamase with cefazolin combined with antimicrobial spacer placement prosthetic joint infection treatment failure. Diagn Microbiol Infect Dis; 2006 Mar;54(3):189-92
Hazardous Substances Data Bank. CEFAZOLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of association of Staphylococcus aureus type A beta-lactamase with cefazolin combined with antimicrobial spacer placement prosthetic joint infection treatment failure.
  • Association of cefazolin treatment failure with type A beta-lactamase-producing Staphylococcus aureus has been suggested.
  • The prevalence of beta-lactamase gene types among 23 methicillin-susceptible S. aureus (MSSA) isolates associated with prosthetic joint infection (PJI) treated with cefazolin was determined using polymerase chain reaction (PCR), and clinical and microbiologic outcomes were assessed.
  • PCR revealed 4 isolates without blaZ, and 12 with type A, 2 with type B, and 5 with type C blaZ.
  • All 13 cases had tissue cultures at time of reimplantation that were negative for S. aureus and 11 had histopathology specimens showing no acute inflammation.
  • Of 8 type A cases undergoing reimplantation, all prostheses remained in place at follow-up (median, 798 days; range, 32-927 days).
  • We conclude that type A blaZ is common in MSSA PJI and that cefazolin therapy for blaZ MSSA PJI can be successful when combined with 2-stage reimplantation and local antimicrobial therapy.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Bacterial Proteins / biosynthesis. Cefazolin / therapeutic use. Joint Prosthesis. Prosthesis-Related Infections / microbiology. Staphylococcal Infections / microbiology. Staphylococcus aureus / drug effects. Staphylococcus aureus / enzymology. beta-Lactamases / biosynthesis
  • [MeSH-minor] DNA, Bacterial / genetics. Humans. Polymerase Chain Reaction. Replantation. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466894.001).
  • [ISSN] 0732-8893
  • [Journal-full-title] Diagnostic microbiology and infectious disease
  • [ISO-abbreviation] Diagn. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Proteins; 0 / DNA, Bacterial; EC 3.5.2.6 / beta-Lactamases; IHS69L0Y4T / Cefazolin
  •  go-up   go-down


28. Ngamvithayapong J, Yanai H, Winkvist A, Saisorn S, Diwan V: Feasibility of home-based and health centre-based DOT: perspectives of TB care providers and clients in an HIV-endemic area of Thailand. Int J Tuberc Lung Dis; 2001 Aug;5(8):741-5
MedlinePlus Health Information. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focus groups were conducted in a high human immunodeficiency virus (HIV) prevalence area of Thailand to elicit perspectives of health staff and clients regarding the feasibility of directly observed therapy (DOT) for tuberculosis.
  • [MeSH-major] Ambulatory Care Facilities. Antitubercular Agents / therapeutic use. Attitude of Health Personnel. Directly Observed Therapy. Endemic Diseases. HIV Infections / epidemiology. Home Care Services. Patient Acceptance of Health Care / statistics & numerical data. Tuberculosis / drug therapy. Tuberculosis / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Home Care Services.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11495265.001).
  • [ISSN] 1027-3719
  • [Journal-full-title] The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • [ISO-abbreviation] Int. J. Tuberc. Lung Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


29. Shimoyama M: [Guideline for phase I study on new anticancer agents]. Gan To Kagaku Ryoho; 2001 Feb;28(2):261-70
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since more than 50% of patients with cancer could no be cured by present standard therapy, new effective anticancer agents are needed in clinical level.
  • This paper shows major parts of a report entitled "Guideline for phase I study on new anticancer agents", already published in JPs Pharmacol Ther 26: 441-454, 1998, with minor modification in order to answer these issues.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials, Phase I as Topic / standards
  • [MeSH-minor] Humans. Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242659.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


30. Duggal A, Barsoum W, Schmitt SK: Patients with prosthetic joint infection on IV antibiotics are at high risk for readmission. Clin Orthop Relat Res; 2009 Jul;467(7):1727-31
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with prosthetic joint infection on IV antibiotics are at high risk for readmission.
  • Due to the rise in prosthetic joint implantations, prosthetic joint infections (PJI) are increasing.
  • Most PJI are treated outside the hospital setting via community-based parenteral antiinfective therapy (CoPAT) after initial surgical management, although little is reported about the short-term complications of CoPAT.
  • We therefore ascertained the numbers of unanticipated readmissions, unplanned surgeries, and CoPAT complications within 12 weeks of hospital discharge in patients with PJI on CoPAT.
  • We retrospectively reviewed the charts of 74 patients with PJI.
  • Our data suggest patients with PJI on CoPAT represent a complex cohort that needs to be monitored closely for complications early after hospital discharge.
  • LEVEL OF EVIDENCE: Level IV, therapeutic study.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Patient Readmission / statistics & numerical data. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2001 Jan;(382):206-16 [11153989.001]
  • [Cites] Clin Infect Dis. 2001 Sep 1;33 Suppl 2:S94-106 [11486305.001]
  • [Cites] J Bone Joint Surg Br. 2002 May;84(4):540-3 [12043775.001]
  • [Cites] N Engl J Med. 2004 Apr 1;350(14):1422-9 [15070792.001]
  • [Cites] Am J Med. 2004 Oct 15;117(8):556-62 [15465503.001]
  • [Cites] N Engl J Med. 2004 Oct 14;351(16):1645-54 [15483283.001]
  • [Cites] Crit Care. 2007;11(2):R31 [17331245.001]
  • [Cites] Semin Arthroplasty. 1993 Jan;4(1):16-24 [10148093.001]
  • [Cites] Clin Infect Dis. 1998 Nov;27(5):1247-54 [9827278.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):731-9 [16481640.001]
  • [Cites] Clin Infect Dis. 2006 Nov 15;43(10):1290-5 [17051494.001]
  • [Cites] J Bone Joint Surg Am. 2007 Mar;89(3):526-33 [17332101.001]
  • [Cites] J Chemother. 2007 Aug;19(4):417-22 [17855186.001]
  • [Cites] Acta Orthop Scand. 1982 Dec;53(6):947-52 [7180407.001]
  • (PMID = 19381747.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC2690761
  •  go-up   go-down


31. Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ: A two-stage retention débridement protocol for acute periprosthetic joint infections. Clin Orthop Relat Res; 2010 Aug;468(8):2029-38
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage retention débridement protocol for acute periprosthetic joint infections.
  • BACKGROUND: Due to the historically poor infection control rates with débridement and component retention for acute periprosthetic infections we developed a new approach for treating acute periprosthetic total joint infections: initial débridement with prosthesis retention and placement of antibiotic-impregnated cement beads followed by a second débridement within 7 days, at which time the beads are removed and new modular parts inserted.
  • QUESTIONS/PURPOSES: We determined the ability of this two-stage débridement to control infection.
  • METHODS: We retrospectively reviewed the charts of 20 patients who underwent this technique; 2 had postoperative and 18 had hematogenous infections.
  • The primary outcome measure was the infection control.
  • RESULTS: Two of the 20 patients had persistent infection.
  • Of the 18 patients without evidence of persistent infection, 10 were no longer on antibiotics at the most recent followup and eight were treated with long-term antibiotics due to compromised host status.
  • CONCLUSIONS: The control of infection in 18 of 20 patients using this technique compares favorably with historical success rates, which range from 24% to 100%.
  • Further research is required to analyze the individual contribution of débridement technique, the use of serial débridements, local depot antibiotics, and combination antibiotic therapy on short-term infection control rates and the long-term persistent control of periprosthetic infection.
  • LEVEL OF EVIDENCE: Level IV, therapeutic study.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Bacterial Infections / therapy. Debridement. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / therapy. Surgical Wound Infection / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Arthroplasty, Replacement, Hip. Arthroplasty, Replacement, Knee. Bone Cements. Combined Modality Therapy. Drug Delivery Systems. Female. Hip Prosthesis / adverse effects. Hip Prosthesis / microbiology. Humans. Knee Prosthesis / adverse effects. Knee Prosthesis / microbiology. Male. Middle Aged. Reoperation. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1999 Oct;81(10):1434-45 [10535593.001]
  • [Cites] Clin Orthop Relat Res. 2008 Nov;466(11):2628-33 [18781372.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):23-8 [12360003.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] Clin Infect Dis. 2003 Apr 1;36(7):845-9 [12652384.001]
  • [Cites] J Arthroplasty. 2003 Oct;18(7 Suppl 1):22-6 [14560406.001]
  • [Cites] J Bone Joint Surg Am. 1974 Mar;56(2):273-84 [4452686.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jun;(117):221-40 [776484.001]
  • [Cites] J Arthroplasty. 1990 Mar;5(1):35-9 [2319246.001]
  • [Cites] J Bone Joint Surg Am. 1990 Oct;72(9):1383-90 [2229118.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):105-12 [1959256.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):113-8 [1959257.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):98-104 [1959294.001]
  • [Cites] Clin Orthop Relat Res. 1992 May;(278):244-52 [1563160.001]
  • [Cites] J Bone Joint Surg Am. 1996 Apr;78(4):512-23 [8609130.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):146-50 [8895631.001]
  • [Cites] J Arthroplasty. 1996 Dec;11(8):931-8 [8986571.001]
  • [Cites] J Arthroplasty. 1997 Jun;12(4):426-33 [9195319.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1999 Mar;28(3):161-5 [10195839.001]
  • [Cites] J Bone Joint Surg Am. 1999 May;81(5):672-83 [10360695.001]
  • [Cites] Arthroscopy. 2005 Mar;21(3):303-6 [15756183.001]
  • [Cites] J Bone Joint Surg Am. 2005 Jul;87(7):1415-22 [15995106.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12(5):433-9 [16643519.001]
  • [Cites] Clin Orthop Relat Res. 2007 Aug;461:130-5 [17438469.001]
  • [Cites] J Bone Joint Surg Am. 2008 Aug;90(8):1637-43 [18676892.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):8-15 [12360001.001]
  • (PMID = 20224958.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2895840
  •  go-up   go-down


32. Byren I, Bejon P, Atkins BL, Angus B, Masters S, McLardy-Smith P, Gundle R, Berendt A: One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother; 2009 Jun;63(6):1264-71
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We describe treatment failure rates by antibiotic duration for prosthetic joint infection (PJI) managed with debridement, antibiotics and implant retention (DAIR).
  • METHODS: We retrospectively collected data from all the cases of PJI that were managed with DAIR over a 5 year period.
  • RESULTS: One hundred and twelve cases of PJI were identified.
  • Twenty infections (18%) recurred during a mean follow-up of 2.3 years.
  • Failure was more common after arthroscopic debridement, for previously revised joints and for Staphylococcus aureus infection.
  • The duration of antibiotic therapy prior to stopping did not predict outcome.
  • CONCLUSIONS: PJI may be managed by DAIR.
  • The risk of failure with this strategy rises after stopping oral antibiotics, but lengthening antibiotic therapy may simply postpone, rather than prevent, failure.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Arthroplasty / adverse effects. Debridement. Prosthesis-Related Infections / drug therapy. Prosthesis-Related Infections / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Arthroplasty. 2003 Oct;18(7 Suppl 1):22-6 [14560406.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jan;86(1):39-42 [14765863.001]
  • [Cites] Clin Infect Dis. 2006 Jan 15;42(2):216-23 [16355332.001]
  • [Cites] J Bone Joint Surg Am. 2004 May;86-A(5):963-74 [15118039.001]
  • [Cites] Infection. 2004 Aug;32(4):222-8 [15293078.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jun;(117):221-40 [776484.001]
  • [Cites] Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S474-80 [6356279.001]
  • [Cites] J Arthroplasty. 1990 Mar;5(1):35-9 [2319246.001]
  • [Cites] J Bone Joint Surg Am. 1990 Oct;72(9):1383-90 [2229118.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):105-12 [1959256.001]
  • [Cites] J Arthroplasty. 2000 Jun;15(4):430-6 [10884201.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):419-30 [11170950.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] J Bone Joint Surg Am. 2003 Jan;85-A(1):20-6 [12533567.001]
  • [Cites] Clin Orthop Relat Res. 2003 Sep;(414):55-60 [12966277.001]
  • [Cites] Clin Infect Dis. 1992 Jun;14(6):1251-3 [1623081.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Jun;37(6):1214-8 [8328772.001]
  • [Cites] J Antimicrob Chemother. 1994 May;33(5):959-67 [8089069.001]
  • [Cites] J Bone Joint Surg Am. 1995 Dec;77(12):1807-13 [8550647.001]
  • [Cites] JAMA. 1996 Mar 20;275(11):858-65 [8596224.001]
  • [Cites] J Bone Joint Surg Am. 1996 Apr;78(4):512-23 [8609130.001]
  • [Cites] Clin Infect Dis. 1997 May;24(5):914-9 [9142792.001]
  • [Cites] J Arthroplasty. 1997 Jun;12(4):426-33 [9195319.001]
  • [Cites] Clin Orthop Relat Res. 1997 Dec;(345):134-9 [9418630.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):948-59 [9596473.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10):2932-9 [9738046.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] Clin Infect Dis. 1998 Oct;27(4):711-3 [9798021.001]
  • [Cites] Clin Infect Dis. 1999 Aug;29(2):292-5 [10476729.001]
  • [Cites] Arthroscopy. 2005 Mar;21(3):303-6 [15756183.001]
  • [Cites] Clin Microbiol Infect. 2005 Oct;11(10):843-5 [16153261.001]
  • [Cites] Stat Med. 2005 Oct 15;24(19):3037-51 [16149126.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):471-8 [16421790.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12(5):433-9 [16643519.001]
  • [Cites] Clin Microbiol Infect. 2006 Sep;12(9):930-3 [16882303.001]
  • [Cites] Am J Med. 2006 Nov;119(11):993.e7-10 [17071171.001]
  • [Cites] J Bone Joint Surg Am. 2007 Apr;89(4):780-5 [17403800.001]
  • [Cites] Clin Microbiol Infect. 2007 Jun;13(6):586-91 [17331125.001]
  • [Cites] J Infect. 2007 Jul;55(1):1-7 [17343916.001]
  • [Cites] J Antimicrob Chemother. 2007 Aug;60(2):356-62 [17566002.001]
  • [Cites] Clin Orthop Relat Res. 2007 Aug;461:130-5 [17438469.001]
  • [Cites] Acta Orthop. 2007 Dec;78(6):755-65 [18236181.001]
  • [ErratumIn] J Antimicrob Chemother. 2013 Dec;68(12):2964-5
  • [ErratumIn] J Antimicrob Chemother. 2011 May;66(5):1203
  • (PMID = 19336454.001).
  • [ISSN] 1460-2091
  • [Journal-full-title] The Journal of antimicrobial chemotherapy
  • [ISO-abbreviation] J. Antimicrob. Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC2680346
  •  go-up   go-down


33. Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K, United Kingdom National Cancer Research Institute Haematological Oncology Study Group: The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol; 2009 May;145(3):318-32
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
  • The acute myeloid leukaemia (AML)14 trial addressed four therapeutic questions in patients predominantly aged over 60 years with AML and High Risk Myelodysplastic Syndrome: (i) Daunorubicin 50 mg/m(2) vs. 35 mg/m(2);.
  • (iii) for part of the trial, patients allocated Daunorubicin 35 mg/m(2) were also randomized to receive, or not, the multidrug resistance modulator PSC-833 in a 1:1:1 randomization; and (iv) a total of three versus four courses of treatment.
  • No benefits were observed in either dose escalation randomization, or from a fourth course of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cyclosporins / administration & dosage. Cytarabine / administration & dosage. Cytogenetic Analysis. Daunorubicin / administration & dosage. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm / drug effects. Female. Humans. Leukocyte Count. Male. Middle Aged. Multivariate Analysis. Prognosis. Remission Induction / methods. Survival Rate

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 May;145(3):333 [19222475.001]
  • (PMID = 19291085.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300133
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclosporins; 04079A1RDZ / Cytarabine; Q7ZP55KF3X / valspodar; ZS7284E0ZP / Daunorubicin
  • [Investigator] Culligan DJ; Tighe J; Craig J; Marcus RE; Cuthbert AC; Cuthbert RJ; Ryan MF; Deeble TJ; Galvani DW; Berney SI; Harvey D; Virchis A; Cuthbert RJ; Jones F; Kettle P; McMullin MF; Morris TC; Fegan C; Johnson RJ; Milligan DW; Pratt GE; Gelly K; Tucker J; Newton LJ; Parapia LA; Williams AT; Bird JM; Evely R; Hows JM; Marks D; Scott GL; Standen GR; Blundell E; Chown S; Dalton RG; Lush R; Ropner J; Collin R; Stewart R; Wodzinski M; Cavet J; Chopra R; Dennis M; Beard J; Clough JV; Rhodes E; Erskine JG; Mccoll M; Micallef-Eynaud PD; Mckernan A; Mitchell DC; Copplestone A; Hamon M; Nokes TJ; Prentice A; Rule S; Chapple MR; Speed K; Paul B; Moosa AH; Dang RK; Abrahamson G; Hedge UM; Philpott N; Gover PA; Grace RJ; Birch AD; Narayanan M; Edwards DR; Gozzard DI; Hoyle C; Mcquaker G; Parker AN; Chown S; Lush R; Hamilton MS; Schey SA; Rahemtulla A; Bynoe AG; Harrison J; Robinson LG; Kaczmarski R; Hoggarth C; Rege K; Houghton JB; Braithwaite JE; Carter C; Ali S; Patil K; Shields ML; Ademokun JA; Chalmers I; Jeha T; Sadullah S; Pocock CF; Kelsey H; Lyttleton M; Wilson-Morkeh I; Akhtar N; Grant I; Mufti G; Pagliuca A; Rowley MR; Sykes H; Child JA; Morgan GJ; Norfolk DR; Smith GM; Chapman CS; Hunter AE; Kennedy B; Snowden JA; Heppleston A; Prangnell DR; Williams C; Sekhar M; Burthem J; Liu Yin JA; Lucas GS; Galvin GP; Jacob A; Aldouri M; White DM; Cook G; Murphy JA; Singer I; Watson WH; Ardeshna K; Basu S; Jacob A; Bowen DT; Cachia PG; Meiklejohn D; Aston L; Milne A; Luckit J; Chasty RC; Chipping PM; Ibbotson RM; Schofield KP; Haines ME; Allard S; Corbett T; Panoskaltsis N; Reid CD; Byrne JL; Haynes AP; Jones PA; Russell NH; Brownell A; Lewis D; Gale RF; Gillett D; Taylor CG; Sivakumaran M; Sobolewski S; Tringham V; Galvin MC; Hillmen P; Wright D; Bell AJ; Jack F; Cranfield T; Dignum H; Ganczakowski M; Coates P; Keidan AJ; Murray JA; Bowcock SJ; Rassam S; Ward S; Forsyth P; Lush C; Murray W; Barker HF; Taylor PC; Brito-Babapulle F; Grech H; Morgenstern G; Hamblin TJ; Killick S; Oscier DG; Joyner MV; Lee R; Pocock M; Rudin C; Ethell M; Kottaridis P; Mehta A; Potter M; Jackson HA; Rees DC; Reilly JT; Snowden J; Winfield DA; Dearden CE; Ethell M; Douglas I; Jones F; McMullin MF; Bareford D; Harrison P; Neilson J; Richardson SG; Cullis JO; Parry HF; Bareford D; Wright JG; Handa S; Hasan Y; Stableforth PJ; Ezekwesili R; Jalihal S; Al-Ismail S; Duncombe A; Orchard K; Richardson D; Smith A; Eden A; Mills MJ; Manson LM; Morrison AE; Dearden CE; Scully M; Behrens J; Clarke M; Rice K; Barnard DL; Johnson R; Mcverry BA; Abdalla SH; Bevan PC; Janes S; Stross P; Carr R; Amos A; Revell P; Leach MT; Watson A; Saied K; Shafeek S; Vosylius P; Blesing NE; Gray AG; Green ES; De Lord CF; Lakhani AK; Vadher B; Grey M; Jip J; Clark RE; Booth F; Roberts P; Rymes N; Smith S; Turner D; Ardeshna K; Devereux S; Goldstone AH; Khwaja A; Linch DC; Nathwani A; Patterson KG; Porter JB; Yong K; Dasgupta R; Olujohungbe A; Sadik W; Woodcock BE; Tillyer ML; Backstrom B; Markevarn B; Sundstrom G; Wahlin A; Burnett AK; Kell J; Poynton C; Rowntree C; Whittaker JA; Bourantas KL; Rogers S; Sharp RA; Tansey P; Jackson N; Strevens MJ; Sadik W; Basu S; Mills J; Rose PE; Dearden CE; Hughes RG; Sekhar M; Davies JM; Ganly P; Johnson PR; Roddie PH; Fitzsimons EJ; Lucie NJ; Soutar R; Anderson CC; DeSilva C; Satchi G; Tappin JA; Gale RF; Allan TL; Stockley R; O'Driscoll AM; Rist CL; Aitchison R; Kelly S; Pattinson J; Bond LR; Howard MR; Gilleece M; Parry H; Seale J
  •  go-up   go-down


34. Mangiantini F, Lorusso M, Pozzi E, Bronzini F, Brondello C, Salvestrini C, Lionetti P: Efficacy of meloxicam in a patient with juvenile polyposis syndrome. J Pediatr Gastroenterol Nutr; 2009 May;48(5):636-8
Hazardous Substances Data Bank. Meloxicam .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of meloxicam in a patient with juvenile polyposis syndrome.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Thiazines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Child. Female. Humans. Mutation, Missense. Treatment Outcome

  • Genetic Alliance. consumer health - Juvenile polyposis syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19412013.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Thiazines; 0 / Thiazoles; 71125-38-7 / meloxicam
  •  go-up   go-down






Advertisement